-
公开(公告)号:NZ502657A
公开(公告)日:2001-06-29
申请号:NZ50265798
申请日:1998-07-23
Applicant: BASF AG
Inventor: TESCHENDORF HANS-JURGEN , GARCIA-LADONA FRANCISCO JAVIER , EMLING FRANZ , WICKE KARSTEN , STEINER GERD , DULLWEBER UTA , STARCK DOROTHEA , BACH ALFRED
IPC: A61K31/435 , A61P25/24 , C07D495/14
Abstract: A 3-substituted 3,4,5,7-tetrahhydropyrrolo[3',4':4,5]-thieno[2,3-d]pyrimidine derivative of the formula I, wherein, R1is a hydrogen atom, a C1-C4 alkyl group, an acetyl group, a phenylalkyl c1-c4 radical where the aromatic ring is unsubstituted or substituted by halogen, C1-C4 alkyl, trifluoromethyl, hydroxyl, C1-C4 alkoxy, amino, cyano or nitro groups, or is a C1-C3 alkyl carboxylate radical, R2 is a phenyl, pyridyl, pyrimidinyl or pyrazinyl group which is unsubstituted or mono or disubstituted by halogen atoms, C1-C4 alkyl, trifluoromethyl, trifluoromethoxy, hydroxyl, C1-C4 alkoxy, amino, monoethylamino, dimethylamino, cyano or nitro groups, and may be fused to a benzene nucleus which may be mono or disubstituted by halogen atoms, C1-C4 alkyl, hydroxyl, trifluoromethyl, C1-C4 alkoxy, amino, cyano or nitro groups and may contain 1 nitrogen atom, or to a 5 or 6 membered ring which may contain 1-2 oxygen atoms, A is NH or an oxygen atom, Y is CH2, CH2-CH2, CH2-CH2-CH2 or CH2-CH, Z is a nitrogen atom, carbon atom or CH, where the linkage between Y and Z may also be a double bond, and n is 2,3 or 4, or a physiologically tolerated salt thereof. These compounds are useful as selective 5HT1B and/or 5HT1A antagonists.
-
公开(公告)号:HRP20000014A2
公开(公告)日:2001-04-30
申请号:HRP20000014
申请日:2000-01-07
Applicant: BASF AG
Inventor: STARCK DOROTHEA , BLANK STEFAN , TREIBER HANS-JOERG , UNGER LILIANE , NEUMANN-SCHULTZ BARBARA , LE-BRIS THEOPHILE-MARIE , TESCHENDORF HANS-JUERGEN , WICKE KARSTEN
IPC: A61K31/33 , A61K31/41 , A61K31/4196 , A61K31/454 , A61K31/506 , A61K31/53 , A61K31/551 , A61P25/00 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/24 , A61P43/00 , C07D249/08 , C07D249/12 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
Abstract: Triazole compounds of the following formula:where Ar1, A, B and Ar2 have the meanings given in the description, possess a high affinity for the dopamine D3 receptor and can therefore be used for treating diseases which respond to dopamine D3 ligands.
-
公开(公告)号:CZ200036A3
公开(公告)日:2001-03-14
申请号:CZ200036
申请日:1998-07-03
Applicant: BASF AG
Inventor: STARCK DOROTHEA , BLANK STEFAN , TREIBER HANS-JOERG , UNGER LILIANE , NEUMANN-SCHULTZ BARBARA , LE BRIS THEOPHILE-MARIE , TESCHENDORF HANS-JUERGEN , WICKE KARSTEN
IPC: A61K31/33 , A61K31/41 , A61K31/4196 , A61K31/454 , A61K31/506 , A61K31/53 , A61K31/551 , A61P25/00 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/24 , A61P43/00 , C07D249/08 , C07D249/12 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
Abstract: Triazole compounds of the following formula:where Ar1, A, B and Ar2 have the meanings given in the description, possess a high affinity for the dopamine D3 receptor and can therefore be used for treating diseases which respond to dopamine D3 ligands.
-
公开(公告)号:HU0002902A2
公开(公告)日:2001-02-28
申请号:HU0002902
申请日:1998-05-29
Applicant: BASF AG
Inventor: DR BACH ALFRED , DULLWEBER UTA , DR EMLING FRANZ , GARCIA-LADONA FRANCISCO-JAVIER , STARCK DOROTHEA , DR STEINER GERD , DR TESCHENDORF HANS-JUERGEN , DR WICKE KARSTEN
IPC: A61K31/495 , A61K31/519 , A61P25/00 , A61P25/24 , A61P43/00 , C07D495/04
Abstract: PCT No. PCT/EP98/03230 Sec. 371 Date Dec. 6, 1999 Sec. 102(e) Date Dec. 6, 1999 PCT Filed May 29, 1998 PCT Pub. No. WO98/56792 PCT Pub. Date Dec. 17, 19983-Substituted 3,4-dihydrothieno[2,3-d]pyrimidine derivatives of the formula I where R1 and R2 are a hydrogen atom or a C1-C4-alkyl group, R3 is a phenyl, pyridyl, pyrimidinyl or pyrazinyl group which is unsubstituted or mono- or disubstituted by halogen atoms, C1-C4-alkyl, trifluoromethyl, trifluoromethoxy, hydroxyl, C1-C4-alkoxy, amino, monomethylamino, dimethylamino, cyano or nitro groups and which may be fused to a benzene nucleus which may be unsubstituted or mono- or disubstituted by halogen atoms, C1-C4-alkyl, hydroxyl, trifluoromethyl, C1-C4-alkoxy, amino, cyano or nitro groups, and may contain 1 nitrogen atom, or to a 5- or 6-membered ring, which may contain 1-2 oxygen atoms, A is NH or an oxygen atom, Y is CH2, CH2-CH2, CH2-CH2-CH2 or CH2-CH, Z is a nitrogen atom, carbon atom or CH, it being possible for the linkage between Y and Z also to be a double bond, and n is 2, 3 or 4, and the physiologically tolerated salts thereof.
-
公开(公告)号:DE19922443A1
公开(公告)日:2000-11-09
申请号:DE19922443
申请日:1999-05-07
Applicant: BASF AG
Inventor: MUEHLBAUER BERND , GROS GERHARD , STARCK DOROTHEA , TREIBER HANS-JOERG
IPC: C07D241/04 , A61K31/00 , A61K31/472 , A61K31/4725 , A61K31/495 , A61K31/496 , A61K31/506 , A61K31/517 , A61K31/5513 , A61K45/00 , A61P1/00 , A61P13/12 , C07D401/12 , C07D403/12 , A61K31/505 , A61K31/47
Abstract: The invention relates to the use of dopamine D3 receptor ligands for producing medicaments for treating kidney disorders.
-
公开(公告)号:NZ502181A
公开(公告)日:2000-10-27
申请号:NZ50218198
申请日:1998-07-03
Applicant: BASF AG
Inventor: STARCK DOROTHEA , BLANK STEFAN , TREIBER HANS-JORG , UNGER LILIANE , NEUMANN-SCHULTZ BARBARA , LE BRIS THEOPHILE-MARIE , TESCHENDORF HANS-JURGEN , WICKE KARSTEN
IPC: A61K31/33 , A61K31/41 , A61K31/4196 , A61K31/454 , A61K31/506 , A61K31/53 , A61K31/551 , A61P25/00 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/24 , A61P43/00 , C07D249/08 , C07D249/12 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
Abstract: Triazole compounds of formula (I) and (VIII), wherein: Ar1 is an optionally substituted aryl or heteroaryl ring that may be fused to a phenyl ring; A is an alkylene optionally interrupted with a group selected from O, S, NR2, CONR2, COO, CO, a double bond and a triple bond; B is a 6 or 7 membered non-aromatic ring containing 1 or 2 nitrogen atoms; and Ar2 is selected from optionally substituted phenyl, pyridyl, pyrimidinyl or triazinyl. The compounds exhibit high dopamine-D3-receptor affinity.
-
公开(公告)号:BR9810017A
公开(公告)日:2000-09-19
申请号:BR9810017
申请日:1998-05-29
Applicant: BASF AG
Inventor: STEINER GERD , HOLZENKAMP UTA , STARCK DOROTHEA , BACH ALFRED , WICKE KARSTEN , TESCHENDORF HANS-JURGE , GARCIA-LADONA FRANCISCO JAVIER , EMLING FRANZ
IPC: A61K31/495 , A61K31/519 , A61P25/00 , A61P25/24 , A61P43/00 , C07D495/04
Abstract: PCT No. PCT/EP98/03230 Sec. 371 Date Dec. 6, 1999 Sec. 102(e) Date Dec. 6, 1999 PCT Filed May 29, 1998 PCT Pub. No. WO98/56792 PCT Pub. Date Dec. 17, 19983-Substituted 3,4-dihydrothieno[2,3-d]pyrimidine derivatives of the formula I where R1 and R2 are a hydrogen atom or a C1-C4-alkyl group, R3 is a phenyl, pyridyl, pyrimidinyl or pyrazinyl group which is unsubstituted or mono- or disubstituted by halogen atoms, C1-C4-alkyl, trifluoromethyl, trifluoromethoxy, hydroxyl, C1-C4-alkoxy, amino, monomethylamino, dimethylamino, cyano or nitro groups and which may be fused to a benzene nucleus which may be unsubstituted or mono- or disubstituted by halogen atoms, C1-C4-alkyl, hydroxyl, trifluoromethyl, C1-C4-alkoxy, amino, cyano or nitro groups, and may contain 1 nitrogen atom, or to a 5- or 6-membered ring, which may contain 1-2 oxygen atoms, A is NH or an oxygen atom, Y is CH2, CH2-CH2, CH2-CH2-CH2 or CH2-CH, Z is a nitrogen atom, carbon atom or CH, it being possible for the linkage between Y and Z also to be a double bond, and n is 2, 3 or 4, and the physiologically tolerated salts thereof.
-
公开(公告)号:BR9810008A
公开(公告)日:2000-09-19
申请号:BR9810008
申请日:1998-05-29
Applicant: BASF AG
Inventor: STEINER GERD , HOLZENKAMP UTA , STARCK DOROTHEA , BACH ALFRED , WICKE KARSTEN , TESCHENDORF HAN-J RGEN , GARCIA-LADONA FRANCISCO JAVIER , EMLING FRANZ
IPC: A61K31/505 , A61K31/519 , A61P25/00 , A61P25/24 , A61P43/00 , C07D495/14
Abstract: PCT No. PCT/EP98/03231 Sec. 371 Date Dec. 8, 1999 Sec. 102(e) Date Dec. 8, 1999 PCT Filed May 29, 1998 PCT Pub. No. WO98/56793 PCT Pub. Date Dec. 17, 19983-Substituted 3,4,5,6,7,8-hexahydropyrido [3',4':4,5]-thieno[2,3-d]pyrimidine derivatives of the formula I where R1 is a hydrogen atom, a C1-C4-alkyl group, an acetyl group, a phenylalkyl C1-C4 radical, the aromatic system being unsubstituted or substituted by halogen, C1-C4-alkyl, trifluoromethyl, hydroxyl, C1-C4-alkoxy, amino, cyano or nitro groups, or is a phenylalkanone radical, it being possible for the phenyl group to be substituted by halogen, R2 is a phenyl, pyridyl, pyrimidinyl or pyrazinyl group which is unsubstituted or mono- or disubstituted by halogen atoms, C1-C4-alkyl, trifluoromethyl, trifluoromethoxy, hydroxyl, C1-C4-alkoxy, amino, monomethylamino, dimethylamino, cyano or nitro groups and which may be fused to a benzene nucleus which can be unsubstituted or mono- or disubstituted by halogen atoms, C1-C4-alkyl, hydroxyl, trifluoromethyl, C1-C4-alkoxy, amino, cyano or nitro groups and may contain 1 nitrogen atom, or to a 5- or 6-membered ring which may contain 1-2 oxygen atoms, A is NH or an oxygen atom, Y is CH2, CH2-CH2, CH2-CH2-CH2 or CH2-CH, Z is a nitrogen atom, carbon atom or CH, it also being possible for the linkage between Y and Z to be a double bond, and n is 2, 3 or 4, and the physiologically tolerated salts thereof.
-
139.
公开(公告)号:CZ20001454A3
公开(公告)日:2000-09-13
申请号:CZ20001454
申请日:1998-10-05
Applicant: BASF AG
Inventor: LUBISCH WILFRIED , DULLWEBER UTA , STARCK DOROTHEA , STEINER GERD , BACH ALFRED , EMLING FRANZ , GARCIA-LADONA XAVIER , TESCHENDORF HANS-JUERGEN , WICKE KARSTEN
IPC: A61K31/519 , A61P25/00 , C07D471/04
-
140.
公开(公告)号:SK3872000A3
公开(公告)日:2000-09-12
申请号:SK3872000
申请日:1998-10-05
Applicant: BASF AG
Inventor: LUBISCH WILFRIED , DULLWEBER UTA , STARCK DOROTHEA , STEINER GERD , BACH ALFRED , EMLING FRANZ , GARCIA-LADONA XAVIER , TESCHENDORF HANS-JURGEN , WICKE KARSTEN
IPC: A61K31/519 , A61P1/00 , A61P1/14 , A61P3/04 , A61P5/00 , A61P9/12 , A61P15/00 , A61P25/00 , A61P25/22 , A61P25/24 , A61P25/28 , A61P43/00 , C07D471/00 , C07D471/04
Abstract: 3-substituted tetrahydropyridopyrimidinone derivatives of the formula (I) wherein the radicals have the meanings given in the Description, to a method for producing said derivatives and, to their use for producing active ingredients for drugs.
-
-
-
-
-
-
-
-
-